# A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

> **NCT00508625** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 213 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** AMG 951 (rhApo2L/TRAIL)
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00508625
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-03
- **Final completion:** 2011-11
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2016-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508625, "A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00508625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*